PT-141 was tested in 43 trials with 3,500 people.

PT-141 acts in the brain

You may first notice that PT-141 is a shot, not a pill. It’s made from seven linked protein pieces. Doctors call PT-141 bremelanotide. The two names refer to one drug. It grew out of work on a lab-made tanning drug.

PT-141 works in the brain. It doesn’t loosen blood vessels or send blood straight to the sex organs. The drug turns on brain cells that help start desire and arousal.

Here’s what matters for you. The FDA approved Vyleesi in 2019. It treats lasting low desire that brings a woman distress. Only women before menopause are covered. Two Phase 3 studies compared a 1.75 mg under-the-skin shot with placebo. A placebo is a look-alike shot with no drug. Desire rose and distress fell more with the drug ^[5][6].

I’d want to see the source before trusting that claim. This page names the study after each finding. It doesn’t sell or prescribe the drug. Before a choice is made, your clinician would need to hear what changed for you, check your blood pressure and heart health, and review every medicine you take now.

PT-141 changed desire before blood flow

Some men find that a blood-flow pill helps the body, but not desire. PT-141 was studied because its first action is in the brain. Sildenafil and similar PDE-5 blood-flow pills relax blood vessels. That lets more blood reach the tissue needed for an erection. PT-141 instead turns on brain cells tied to interest and drive ^[10][15].

The early tests were small, and many used animals. In male rats, the drug increased courtship without changing movement or the later sex act ^[10]. Female rats sought a mate more, while other sex responses stayed much the same ^[16]. A rat can’t tell us what you’ll feel.

One study gave women a 1.75 mg under-the-skin shot before a brain scan ^[17]. The women viewed sexual images. Some brain areas became busier, while another became less busy. Two areas also worked together more. Researchers thought the women may have watched and judged themselves less.

PT-141 is made from seven protein pieces joined into a loop. The loop slows how fast the body breaks the drug down. At higher use, the drug can also turn on the skin-color system and cause dark patches ^[9].

Here’s the larger point. This was the first drug of its type tested in both men and women. It’s still the only one that finished a Phase 3 plan ^[11]. Before any choice, your clinician would check your health, other drugs, and the change that brought you in. Animal findings can’t tell you what you’ll feel.

PT-141 helped some women and men in studies

Desire can fade even when you still care about a partner, and PT-141 was studied for that kind of loss because the drug acts on brain cells that help start desire. Across 43 studies, about 3,500 people took part ^[9]. That’s a broad record, but it can’t promise your result.

The strongest work involved women with a troubling loss of desire before menopause. In one Phase 3 test, more women felt help than after placebo. A second Phase 3 report agreed. About 58% improved with PT-141, compared with 36% on placebo ^[5]. A 52-week follow-up found that the benefit lasted. No new harm appeared through 76 weeks ^[14].

The work in men stopped earlier. Phase 2 tests found more erections as the amount rose. That held for healthy men and some men who got too little help from sildenafil. The nasal amounts were above 7 mg. Shots used 4-6 mg ^[1][2]. The FDA hasn’t approved PT-141 for men.

One short study also looked at food. Women with obesity got three daily doses for 15 days. They ate fewer calories each day than women on placebo ^[19]. That result isn’t an approved use. I’d ask your clinician which findings match your age, health, medicines, and main concern. Those group averages won’t tell you which change you’d notice.

PT-141 has one FDA-approved use

You may see PT-141 named online for many uses. The legal approval is much narrower. On June 21, 2019, the FDA approved Vyleesi, the brand name. The product is a 1.75 mg under-the-skin shot. It treats lasting low desire that distresses women before menopause.

The label says to use one 1.75 mg shot at least 45 minutes before sex. It allows one dose during any 24 hours and eight in a month. The label also says to stop after 8 weeks with no benefit ^[6]. That’s the label, not advice for you.

The drug can cause a short rise in blood pressure. People with uncontrolled blood pressure or known heart and blood-vessel disease can’t use it ^[8]. The approval doesn’t cover men or women past menopause.

The same drug sold only for lab work falls under other rules. This page doesn’t cover that market. I’d expect your clinician to hear what changed, check your risks, and say whether the approved use matches you. The label can’t replace a visit about the risks you’d face.

PT-141 prescription care has more than one route

The FDA-approved bremelanotide product needs a prescription in the United States. PT-141 is another name for bremelanotide. It treats lasting low desire that distresses women before menopause. A clinician first checks the woman’s health and makes the diagnosis.

PT-141 labeled for lab research remains on sale under separate rules. Compounded PT-141 can also be prescribed after an individual review, but the compounded preparation has no FDA approval. A clinician may turn down a request; the patient’s state and the treatment each limit the options. This reading guide does not diagnose, examine, or prescribe for anyone.

PT-141 research looked at desire, erections, and food

The studies asked (1) whether the drug could help a changed sexual response and (2) how the drug worked. The approved work involved women with a troubling loss of desire before menopause. Work on trouble getting an erection reached Phase 2, but not approval.

Researchers also asked how the brain starts arousal and desire. They focused on brain cells the drug turns on.

A smaller set of studies followed appetite and weight. In Phase 1 tests, some women ate less ^[19]. Scientists still study why one brain area may affect sex and hunger ^[18]. Here’s my dividing line: a research question isn’t an approved use for you. Hunger research can’t answer your concern, and it won’t approve a new use for you.